Dr Robert Day
Université de Sherbrooke
Targeting an “evil twin” enzyme in prostate cancer
Once prostate cancer spreads, men have few treatment options. Dr Robert Day and his team are developing a new approach to therapy that blocks an enzyme called PACE4. In recent work, they made the unexpected discovery that an “evil twin” version of PACE4 is created in prostate cancer cells to drive their growth. This helped explain how the drug they are developing works. The researchers also found high levels of the alternate PACE4 in other cancer types like lung and pancreatic cancers, suggesting it could be a new therapeutic target for many hard-to-treat tumours.
Learn more about the impact of our research, supported by your donations.